Trial Profile
A Phase 1, Open-label Study of the Safety, Pharmacokinetics and Efficacy of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Apr 2024
Price :
$35
*
At a glance
- Drugs RX 108 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Suzhou NeuPharma
- 12 Apr 2022 Planned End Date changed from 1 Dec 2021 to 1 Aug 2023.
- 12 Apr 2022 Planned primary completion date changed from 1 Aug 2021 to 1 Aug 2023.
- 03 Oct 2020 Planned End Date changed from 1 Sep 2020 to 1 Dec 2021.